MediWound Ltd.(MDWD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $31.8M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MDWD Stock Analysis & AI Quality Score
AI stock analysis and institutional research for MediWound Ltd. (MDWD), a Healthcare sector company. MDWD is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $31.8m in revenue. Based on the latest XBRL financial filings (FY 2025), MediWound Ltd. reports quarterly revenue of $17.0M, net income of $-23.9M. Top institutional holders of MDWD by reported 13-F value include INVESTOR AB, Yelin Lapidot Holdings Management Ltd., Rosalind Advisors,, based on the most recent SEC filings. MDWD trades on the Nasdaq exchange and files with the SEC under CIK 1593984. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MDWD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MediWound Ltd. directly from SEC EDGAR.
Revenue
FY 2025
$17.0M
Net Income
FY 2025
$-23.9M
Get alerted when MDWD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for MediWound Ltd. including:
Top Institutional Holders of MDWD
INVESTOR AB
$14.0M872,093 shYelin Lapidot Holdings Management Ltd.
$12.3M762,817 shRosalind Advisors, Inc.
$12.1M749,054 shBlackRock, Inc.
$7.2M445,834 shMEITAV INVESTMENT HOUSE LTD
$6.0M371,868 shSPHERA FUNDS MANAGEMENT LTD.
$4.4M273,192 shSilverberg Bernstein Capital Management LLC
$3.2M200,005 shPoint72 Asset Management, L.P.
$2.8M175,479 shUBS Group AG
$2.6M159,791 shSTATE STREET CORP
$2.3M143,770 sh
| Fund | Value | Shares |
|---|---|---|
| INVESTOR AB | $14.0M | 872,093 |
| Yelin Lapidot Holdings Management Ltd. | $12.3M | 762,817 |
| Rosalind Advisors, Inc. | $12.1M | 749,054 |
| BlackRock, Inc. | $7.2M | 445,834 |
| MEITAV INVESTMENT HOUSE LTD | $6.0M | 371,868 |
| SPHERA FUNDS MANAGEMENT LTD. | $4.4M | 273,192 |
| Silverberg Bernstein Capital Management LLC | $3.2M | 200,005 |
| Point72 Asset Management, L.P. | $2.8M | 175,479 |
| UBS Group AG | $2.6M | 159,791 |
| STATE STREET CORP | $2.3M | 143,770 |
More Healthcare Companies
View all Healthcare →Put MDWD on your watchlist
Track score changes the day MediWound Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MDWD a good stock to buy?
13F Pro's AI-powered analysis of MediWound Ltd. (MDWD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MDWD are available on the MDWD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own MDWD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MDWD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MediWound Ltd.'s investment landscape.